Abstract
The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.
| Original language | English |
|---|---|
| Pages (from-to) | 608-610 |
| Number of pages | 3 |
| Journal | Therapeutic Drug Monitoring |
| Volume | 15 |
| Issue number | 6 |
| State | Published - 1993 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Health, Toxicology and Mutagenesis
- Public Health, Environmental and Occupational Health
- Toxicology
Cite this
Use of therapeutic drug monitoring in pharmacoeconomics. / Destache, Christopher J.
In: Therapeutic Drug Monitoring, Vol. 15, No. 6, 1993, p. 608-610.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of therapeutic drug monitoring in pharmacoeconomics
AU - Destache, Christopher J.
PY - 1993
Y1 - 1993
N2 - The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.
AB - The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.
UR - http://www.scopus.com/inward/record.url?scp=0027438073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027438073&partnerID=8YFLogxK
M3 - Article
VL - 15
SP - 608
EP - 610
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
SN - 0163-4356
IS - 6
ER -